Pharmacologic and Non-Pharmacologic Dyspnea Management in Advanced Cancer Patients.
Rachel A ZemelPublished in: The American journal of hospice & palliative care (2021)
As there is a high propensity for patients with advanced malignancy to experience refractory dyspnea, it is necessary for physicians to be well-versed in the management of these patients' dyspneic symptoms. For symptomatic treatment of cancer patients with dyspnea, both pharmacologic and non-pharmacologic methods should be considered. The main source of pharmacologic symptom management for dyspnea is oral and parenteral opioids; benzodiazepines and corticosteroids may serve as helpful adjuncts alongside opioid treatments. However, oxygen administration and nebulized loop diuretics have not been shown to clinically benefit dyspneic cancer patients. Applying non-pharmacologic dyspnea management methods may be valuable palliative therapies for advanced cancer patients, as they provide benefit with negligible harm to the patient. Advantageous and minimally harmful non-pharmacologic dyspnea therapies include facial airflow, acupuncture and/or acupressure, breathing exercises, cognitive behavioral therapy, music therapy, and spiritual interventions. Thus, it is vital that physicians are prepared to provide symptomatic care for dyspnea in advanced cancer patients as to minimize suffering in this patient population during definitive cancer treatments or hospice care.
Keyphrases
- advanced cancer
- palliative care
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- healthcare
- ejection fraction
- primary care
- papillary thyroid
- pain management
- prognostic factors
- peritoneal dialysis
- quality improvement
- radiation therapy
- mesenchymal stem cells
- case report
- squamous cell
- patient reported outcomes
- high intensity
- body composition
- stem cells
- bone marrow
- resistance training
- locally advanced
- sleep quality
- combination therapy